Literature DB >> 9348103

The role of amyloid in the pathogenesis of Alzheimer's disease.

M M Verbeek1, D J Ruiter, R M de Waal.   

Abstract

Since the identification in 1984 of the amyloid beta protein (Abeta) as the major component of senile plaques and cerebrovascular amyloid in Alzheimer's disease (AD) brains, it is well accepted that the production of this protein is a crucial factor in the pathogenesis of AD. Abeta is produced by cleavage from the amyloid precursor protein (APP) and can form fibrils in vivo and in vitro. The formation of these fibrils is influenced by proteins that are found in association with Abeta-containing lesions in the AD brain. Several of these proteins arise by an inflammatory response of the brain to Abeta production. The distribution of different isoforms of Abeta, varying at the C-terminus of the peptide, varies among the Abeta-containing lesions in AD brains. Such variations may have consequences for the pathogenesis of AD because the various Abeta isoforms differ in their capacity to form fibrils, and they have different toxic effects on neurons and vascular cells, respectively. The experimental data indicate that the pathogenesis of senile plaques is different from the generation of cerebrovascular amyloidosis. Summarizing models for either type of AD pathology are presented.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9348103     DOI: 10.1515/bchm.1997.378.9.937

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  6 in total

1.  Mass spectrometry-based screening for inhibitors of beta-amyloid protein aggregation.

Authors:  Xun Cheng; Richard B van Breemen
Journal:  Anal Chem       Date:  2005-11-01       Impact factor: 6.986

2.  Multifunctional liposomes reduce brain β-amyloid burden and ameliorate memory impairment in Alzheimer's disease mouse models.

Authors:  Claudia Balducci; Simona Mancini; Stefania Minniti; Pietro La Vitola; Margherita Zotti; Giulio Sancini; Mario Mauri; Alfredo Cagnotto; Laura Colombo; Fabio Fiordaliso; Emanuele Grigoli; Mario Salmona; Anniina Snellman; Merja Haaparanta-Solin; Gianluigi Forloni; Massimo Masserini; Francesca Re
Journal:  J Neurosci       Date:  2014-10-15       Impact factor: 6.167

Review 3.  Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease.

Authors:  Fernanda G De Felice; Sérgio T Ferreira
Journal:  Cell Mol Neurobiol       Date:  2002-12       Impact factor: 5.046

4.  Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease.

Authors:  Kaan E Biron; Dara L Dickstein; Rayshad Gopaul; Wilfred A Jefferies
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

5.  Amyloid-precursor-protein-lowering small molecules for disease modifying therapy of Alzheimer's disease.

Authors:  Sina Cathérine Rosenkranz; Markus Geissen; Kristina Härter; Beata Szalay; Isidro Ferrer; Jana Vogel; Stephen Smith; Markus Glatzel
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

Review 6.  Autophagy Modulation as a Treatment of Amyloid Diseases.

Authors:  Zoe Mputhia; Eugene Hone; Timir Tripathi; Tim Sargeant; Ralph Martins; Prashant Bharadwaj
Journal:  Molecules       Date:  2019-09-16       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.